Tag: Eli Lilly and Co

Drugmakers race to find a place in the next wave of obesity drugs

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jim Cramer says he can’t sell Eli Lilly despite its massive run up. Here’s why

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Weight loss drug maker sinks 25% after new safety data spooks investors

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Eli Lilly’s top dealmaker says don’t be surprised to see more M&A that pushes Lilly into new areas

CVS to restore coverage of Zepbound, add Eli Lilly’s obesity pill to drug plans

Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know

Signos grows foothold in weight-loss wave fueled by GLP-1s with its AI health data tracking